PDCD1 and rheumatoid arthritis: Therefore, therapeutic targeting of the PD-1 pathway locally in the RA ST has the potential to affect both B and T cells in the treatment of early RA and thus, may provide deeper responses and higher remission rates than the current generation of therapeutics.